Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases

Authors: Rainer J. Klement, N. Abbasi-Senger, S. Adebahr, H. Alheid, M. Allgaeuer, G. Becker, O. Blanck, J. Boda-Heggemann, T. Brunner, M. Duma, M. J. Eble, I. Ernst, S. Gerum, D. Habermehl, P. Hass, C. Henkenberens, G. Hildebrandt, D. Imhoff, H. Kahl, N. D. Klass, R. Krempien, V. Lewitzki, F. Lohaus, C. Ostheimer, A. Papachristofilou, C. Petersen, J. Rieber, T. Schneider, E. Schrade, R. Semrau, S. Wachter, A. Wittig, M. Guckenberger, N. Andratschke

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer.

Methods

The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS.

Results

Three hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months indicating better survival with LC.

Conclusion

In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.
Literature
1.
2.
Patanaphan V, Salazar OM. Colorectal cancer: metastatic patterns and prognosis. South Med J. 1993;86:38–41.CrossRefPubMed
3.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18 discussion 318-21.CrossRefPubMedCentralPubMed
4.
Casiraghi M, De PT, Brambilla D, Ciprandi B, Galetta D, Borri A, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “international registry of lung metastases.”. J Thorac Oncol. 2011;6:1373–8.CrossRefPubMed
5.
Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, et al. Differences between Colon Cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential Oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys. 2015;92:837–42.CrossRefPubMedCentralPubMed
6.
MacDermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of Oligometastases with radiotherapy. J Surg Oncol. 2008;98:202–6.CrossRefPubMed
7.
Salama J, Hasselle M, Chmura S. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer. 2012;118:2962–70.CrossRefPubMed
8.
Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;0:578–83.
9.
Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9).
10.
Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases - a pooled analysis of the German working group “stereotactic radiotherapy”. Lung Cancer. 2016;97:51–8.CrossRefPubMed
11.
Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123:227–33.CrossRefPubMed
12.
Rondeau V, Pignon J-P, Michiels S. A joint model for the dependence between clustered times to tumour progression and deaths: a meta-analysis of chemotherapy in head and neck cancer. Stat Methods Med Res. 2011;32:5380.
13.
14.
Duchateau L, Janssen P. The frailty model. 1st ed. New York: Springer science+business Media; 2008.
15.
Xu J, Kalbfleisch JD, Tai B. Statistical analysis of illness-death processes and semicompeting risks data. Biometrics. 2010;66:716–25.CrossRefPubMed
16.
Rondeau V, Mazroui Y, Gonzalez JR. Frailtypack: an R package for the analysis of correlated survival data with frailty models using penalized likelihood estimation or parametrical estimation. J Stat Softw. 2012;47:1–28.CrossRef
17.
Harrell FE Jr. Regression Modeling Strategies. 2nd ed. New York: Springer; 2015.CrossRef
18.
Van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.CrossRef
19.
Gelman A. Scaling regression inputs by dividing by two standard deviations. Stat Med. 2008;27:2865–73.CrossRefPubMed
20.
21.
Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–86.CrossRefPubMed
22.
Angelsen J-H, Horn A, Eide GE, Viste A. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol. 2014;12:127.CrossRefPubMedCentralPubMed
23.
Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 2006;45:808–17.CrossRefPubMed
24.
Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67:793–8.CrossRefPubMed
25.
Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, M a C, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–84.CrossRefPubMed
26.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.CrossRefPubMed
27.
Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol (Madr). 2006;45:838–47.CrossRef
28.
Stintzing S, Hoffmann R-T, Heinemann V, Kufeld M, Rentsch M, Muacevic A. Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol. 2010;17:2877–83.CrossRefPubMed
29.
Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101:255–9.CrossRefPubMed
30.
Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6:369–74.PubMedPubMedCentral
31.
Thibault I, Poon I, Yeung L, Erler D, Kim A, Keller B, et al. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution’s comprehensive experience. Clin Oncol (R Coll Radiol). 2014;26:713–9.CrossRef
32.
Andratschke N, Parys A, Stadtfeld S, Wurster S, Huttenlocher S, Imhoff D, et al. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiat Oncol. 2016;11:74.CrossRefPubMedCentralPubMed
33.
Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95:1399–404.CrossRefPubMedCentralPubMed
34.
Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, et al. Bayesian cure rate modeling of local tumor control: evaluation in stereotactic body radiotherapy for pulmonary metastases. Int J Radiat Oncol. 2016;94:841–9.CrossRef
35.
Klement RJ. Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiother Oncol. 2017;123:218–26.CrossRefPubMed
36.
Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal Cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for Metachronous liver metastases. Ann Surg. 2012;256:642–50.CrossRefPubMed
37.
Russo F, Williamson J. Interpreting causality in the health sciences. Int Stud Philos Sci. 2007;21:157–70.CrossRef
38.
Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, et al. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017;123:182–8.CrossRefPubMed
Metadata
Title
The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases
Authors
Rainer J. Klement
N. Abbasi-Senger
S. Adebahr
H. Alheid
M. Allgaeuer
G. Becker
O. Blanck
J. Boda-Heggemann
T. Brunner
M. Duma
M. J. Eble
I. Ernst
S. Gerum
D. Habermehl
P. Hass
C. Henkenberens
G. Hildebrandt
D. Imhoff
H. Kahl
N. D. Klass
R. Krempien
V. Lewitzki
F. Lohaus
C. Ostheimer
A. Papachristofilou
C. Petersen
J. Rieber
T. Schneider
E. Schrade
R. Semrau
S. Wachter
A. Wittig
M. Guckenberger
N. Andratschke
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5362-5

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Study protocol

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

Research article

Interaction between TP53 and XRCC1 increases susceptibility to cervical cancer development: a case control study

Research article

Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany

Research article

Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

Research article

Detection of carcinogen-induced bladder cancer by fluorocoxib A

Research article

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits